Hepatitis Monthly

Published by: Kowsar

Neuropsychiatric and Psychosocial Issues of Patients With Hepatitis C Infection: A Selective Literature Review

Amirhossein Modabbernia 1 , 2 , Hossein Poustchi 1 and Reza Malekzadeh 1 , *
Authors Information
1 Digestive Disease Research Centre, Shariati Hospital, Tehran University of Medical Sciences, Tehran, IR Iran
2 Psychiatric Research Centre, Roozbeh Hospital, Tehran University of Medical Sciences, Tehran, IR Iran
Article information
  • Hepatitis Monthly: January 2013, 13 (1); e8340
  • Published Online: January 7, 2013
  • Article Type: Review Article
  • Received: August 1, 2012
  • Revised: August 20, 2012
  • Accepted: October 8, 2012
  • DOI: 10.5812/hepatmon.8340

To Cite: Modabbernia A, Poustchi H, Malekzadeh R. Neuropsychiatric and Psychosocial Issues of Patients With Hepatitis C Infection: A Selective Literature Review, Hepat Mon. 2013 ;13(1):e8340. doi: 10.5812/hepatmon.8340.

Abstract
Copyright: Copyright © 2013, Hepatitis Monthly. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited..
1. Context
2. Evidence Acquisition
3. Results
4. Conclusions
Acknowledgements
Footnotes
References
  • 1. Bonkovsky HL, Snow KK, Malet PF, Back-Madruga C, Fontana RJ, Sterling RK, et al. Health-related quality of life in patients with chronic hepatitis C and advanced fibrosis. J Hepatol. 2007; 46(3): 420-31[DOI][PubMed]
  • 2. Ghany MG, Strader DB, Thomas DL, Seeff LB. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology. 2009; 49(4): 1335-74[DOI][PubMed]
  • 3. Crone C, Gabriel GM. Comprehensive review of hepatitis C for psychiatrists: risks, screening, diagnosis, treatment, and interferon-based therapy complications. J Psychiatr Pract. 2003; 9(2): 93-110[PubMed]
  • 4. Forton DM, Thomas HC, Taylor-Robinson SD. Quality of life and cognitive function in chronic hepatitis C - what to measure? J Hepatol. 2003; 39(2): 272-4[PubMed]
  • 5. Foster GR. Quality of life considerations for patients with chronic hepatitis C. J Viral Hepat. 2009; 16(9): 605-11[DOI][PubMed]
  • 6. Spiegel BM, Younossi ZM, Hays RD, Revicki D, Robbins S, Kanwal F. Impact of hepatitis C on health related quality of life: a systematic review and quantitative assessment. Hepatology. 2005; 41(4): 790-800[DOI][PubMed]
  • 7. Miller ER, McNally S, Wallace J, Schlichthorst M. The ongoing impacts of hepatitis c - a systematic narrative review of the literature. BMC Public Health. 2012; 12(1): 672[DOI][PubMed]
  • 8. Amodio P, Salari L, Montagnese S, Schiff S, Neri D, Bianco T, et al. Hepatitis C virus infection and health-related quality of life. World J Gastroenterol. 2012; 18(19): 2295-9[DOI][PubMed]
  • 9. Ashrafi M, Modabbernia A, Dalir M, Taslimi S, Karami M, Ostovaneh MR, et al. Predictors of mental and physical health in non-cirrhotic patients with viral hepatitis: A case control study. J Psychosom Res. 2012; 73(3): 218-24[DOI][PubMed]
  • 10. Foster GR, Goldin RD, Thomas HC. Chronic hepatitis C virus infection causes a significant reduction in quality of life in the absence of cirrhosis. Hepatology. 1998; 27(1): 209-12[DOI][PubMed]
  • 11. Modabbernia A, Ashrafi M, Keyvani H, Taslimi S, Poorkaveh A, Merat S, et al. Brain-derived neurotrophic factor predicts physical health in untreated patients with hepatitis C. Biol Psychiatry. 2011; 70(5)-2[DOI][PubMed]
  • 12. Bondini S, Kallman J, Dan A, Younoszai Z, Ramsey L, Nader F, et al. Health-related quality of life in patients with chronic hepatitis B. Liver Int. 2007; 27(8): 1119-25[DOI][PubMed]
  • 13. Dan AA, Kallman JB, Wheeler A, Younoszai Z, Collantes R, Bondini S, et al. Health-related quality of life in patients with non-alcoholic fatty liver disease. Aliment Pharmacol Ther. 2007; 26(6): 815-20[DOI][PubMed]
  • 14. Forton DM, Allsop JM, Main J, Foster GR, Thomas HC, Taylor-Robinson SD. Evidence for a cerebral effect of the hepatitis C virus. Lancet. 2001; 358(9275): 38-9[DOI][PubMed]
  • 15. Forton DM, Thomas HC, Murphy CA, Allsop JM, Foster GR, Main J, et al. Hepatitis C and cognitive impairment in a cohort of patients with mild liver disease. Hepatology. 2002; 35(2): 433-9[DOI][PubMed]
  • 16. Forton DM, Allsop JM, Cox IJ, Hamilton G, Wesnes K, Thomas HC, et al. A review of cognitive impairment and cerebral metabolite abnormalities in patients with hepatitis C infection. AIDS. 2005; 19 Suppl 3-63[PubMed]
  • 17. Forton DM, Taylor-Robinson SD, Thomas HC. Cerebral dysfunction in chronic hepatitis C infection. J Viral Hepat. 2003; 10(2): 81-6[PubMed]
  • 18. Hilsabeck RC, Perry W, Hassanein TI. Neuropsychological impairment in patients with chronic hepatitis C. Hepatology. 2002; 35(2): 440-6[DOI][PubMed]
  • 19. Kramer L, Hofer H, Bauer E, Funk G, Formann E, Steindl-Munda P, et al. Relative impact of fatigue and subclinical cognitive brain dysfunction on health-related quality of life in chronic hepatitis C infection. AIDS. 2005; 19 Suppl 3-92[PubMed]
  • 20. Bownik H, Saab S. The effects of hepatitis C recurrence on health-related quality of life in liver transplant recipients. Liver Int. 2010; 30(1): 19-30[DOI][PubMed]
  • 21. Poynard T, Cacoub P, Ratziu V, Myers RP, Dezailles MH, Mercadier A, et al. Fatigue in patients with chronic hepatitis C. J Viral Hepat. 2002; 9(4): 295-303[PubMed]
  • 22. Seaman K, Paterson BL, Vallis M, Hirsch G, Peltekian KM. Future directions for investigation of fatigue in chronic hepatitis C viral infection. Chronic Illn. 2009; 5(2): 115-28[DOI][PubMed]
  • 23. Racciatti D, Gorgoretti V, Sepede G, Gambi F, Pizzigallo E. An Italian study on health-related quality of life and fatigue in patients with chronic fatigue syndrome and patients with chronic HCV virus infection: similarities and differences. Int J Immunopathol Pharmacol. 2011; 24(3): 673-81[PubMed]
  • 24. Barkhuizen A, Rosen HR, Wolf S, Flora K, Benner K, Bennett RM. Musculoskeletal pain and fatigue are associated with chronic hepatitis C: a report of 239 hepatology clinic patients. Am J Gastroenterol. 1999; 94(5): 1355-60[DOI][PubMed]
  • 25. Hilsabeck RC, Hassanein TI, Perry W. Biopsychosocial predictors of fatigue in chronic hepatitis C. J Psychosom Res. 2005; 58(2): 173-8[DOI][PubMed]
  • 26. Anty R, Marjoux S, Bekri S, DeGalleani L, Dainese R, Gelsi E, et al. Plasma carnitine is associated with fatigue in chronic hepatitis C but not in the irritable bowel syndrome. Aliment Pharmacol Ther. 2011; 33(8): 961-8[DOI][PubMed]
  • 27. El-Gindy EM, Ali-Eldin FA, Meguid MA. Serum leptin level and its association with fatigue in patients with chronic hepatitis C virus infection. Arab J Gastroenterol. 2012; 13(2): 54-7[DOI][PubMed]
  • 28. Sarkar S, Jiang Z, Evon DM, Wahed AS, Hoofnagle JH. Fatigue before, during and after antiviral therapy of chronic hepatitis C: Results from the Virahep-C study. J Hepatol. 2012; 57(5): 946-52[DOI][PubMed]
  • 29. Felger JC, Alagbe O, Pace TW, Woolwine BJ, Hu F, Raison CL, et al. Early activation of p38 mitogen activated protein kinase is associated with interferon-alpha-induced depression and fatigue. Brain Behav Immun. 2011; 25(6): 1094-8[DOI][PubMed]
  • 30. Felger JC, Cole SW, Pace TW, Hu F, Woolwine BJ, Doho GH, et al. Molecular signatures of peripheral blood mononuclear cells during chronic interferon-alpha treatment: relationship with depression and fatigue. Psychol Med. 2012; 42(8): 1591-603[DOI][PubMed]
  • 31. Kronenberger B, Berg T, Herrmann E, Hinrichsen H, Gerlach T, Buggisch P, et al. Efficacy of amantadine on quality of life in patients with chronic hepatitis C treated with interferon-alpha and ribavirin: results from a randomized, placebo-controlled, double-blind trial. Eur J Gastroenterol Hepatol. 2007; 19(8): 639-46[DOI][PubMed]
  • 32. Malaguarnera M, Vacante M, Bertino G, Neri S, Gargante MP, Motta M, et al. The supplementation of acetyl-L-carnitine decreases fatigue and increases quality of life in patients with hepatitis C treated with pegylated interferon-alpha 2b plus ribavirin. J Interferon Cytokine Res. 2011; 31(9): 653-9[DOI][PubMed]
  • 33. Martin KA, Krahn LE, Balan V, Rosati MJ. Modafinil's use in combating interferon-induced fatigue. Dig Dis Sci. 2007; 52(4): 893-6[DOI][PubMed]
  • 34. Rabkin JG, McElhiney MC, Rabkin R. Modafinil and armodafinil treatment for fatigue for HIV-positive patients with and without chronic hepatitis C. Int J STD AIDS. 2011; 22(2): 95-101[DOI][PubMed]
  • 35. Goulding C, O'Connell P, Murray FE. Prevalence of fibromyalgia, anxiety and depression in chronic hepatitis C virus infection: relationship to RT-PCR status and mode of acquisition. Eur J Gastroenterol Hepatol. 2001; 13(5): 507-11[PubMed]
  • 36. Kozanoglu E, Canataroglu A, Abayli B, Colakoglu S, Goncu K. Fibromyalgia syndrome in patients with hepatitis C infection. Rheumatol Int. 2003; 23(5): 248-51[DOI][PubMed]
  • 37. Mohammad A, Carey JJ, Storan E, Scarry M, Coughlan RJ, Lee JM. Prevalence of fibromyalgia among patients with chronic hepatitis C infection: relationship to viral characteristics and quality of life. J Clin Gastroenterol. 2012; 46(5): 407-12[DOI][PubMed]
  • 38. Mohammed RH, ElMakhzangy HI, Gamal A, Mekky F, El Kassas M, Mohammed N, et al. Prevalence of rheumatologic manifestations of chronic hepatitis C virus infection among Egyptians. Clin Rheumatol. 2010; 29(12): 1373-80[DOI][PubMed]
  • 39. Morasco BJ, Huckans M, Loftis JM, Woodhouse J, Seelye A, Turk DC, et al. Predictors of pain intensity and pain functioning in patients with the hepatitis C virus. Gen Hosp Psychiatry. 2010; 32(4): 413-8[DOI][PubMed]
  • 40. Rifai MA, Indest D, Loftis J, Hauser P. Psychiatric management of the hepatitis C patient. Curr Treat Options Gastroenterol. 2006; 9(6): 508-19[PubMed]
  • 41. Schaefer M, Capuron L, Friebe A, Diez-Quevedo C, Robaeys G, Neri S, et al. Hepatitis C infection, antiviral treatment and Mental Health: A European Expert Consensus Statement. J Hepatol. 2012; 57(6): 1379-90[DOI][PubMed]
  • 42. Rifai MA, Gleason OC, Sabouni D. Psychiatric care of the patient with hepatitis C: a review of the literature. Prim Care Companion J Clin Psychiatry. 2010; 12(6)[DOI][PubMed]
  • 43. McMahon JM, Tortu S. A potential hidden source of hepatitis C infection among noninjecting drug users. J Psychoactive Drugs. 2003; 35(4): 455-60[PubMed]
  • 44. el-Serag HB, Kunik M, Richardson P, Rabeneck L. Psychiatric disorders among veterans with hepatitis C infection. Gastroenterology. 2002; 123(2): 476-82[PubMed]
  • 45. Fontana RJ, Hussain KB, Schwartz SM, Moyer CA, Su GL, Lok AS. Emotional distress in chronic hepatitis C patients not receiving antiviral therapy. J Hepatol. 2002; 36(3): 401-7[PubMed]
  • 46. Zickmund S, Hillis SL, Barnett MJ, Ippolito L, LaBrecque DR. Hepatitis C virus-infected patients report communication problems with physicians. Hepatology. 2004; 39(4): 999-1007[DOI][PubMed]
  • 47. Gitto S, Micco L, Conti F, Andreone P, Bernardi M. Alcohol and viral hepatitis: a mini-review. Dig Liver Dis. 2009; 41(1): 67-70[DOI][PubMed]
  • 48. Raison CL, Demetrashvili M, Capuron L, Miller AH. Neuropsychiatric adverse effects of interferon-alpha: recognition and management. CNS Drugs. 2005; 19(2): 105-23[PubMed]
  • 49. Ping F, Shang J, Zhou J, Zhang H, Zhang L. 5-HT(1A) receptor and apoptosis contribute to interferon-alpha-induced "depressive-like" behavior in mice. Neurosci Lett. 2012; 514(2): 173-8[DOI][PubMed]
  • 50. Kenis G, Prickaerts J, van Os J, Koek GH, Robaeys G, Steinbusch HW, et al. Depressive symptoms following interferon-alpha therapy: mediated by immune-induced reductions in brain-derived neurotrophic factor? Int J Neuropsychopharmacol. 2011; 14(2): 247-53[DOI][PubMed]
  • 51. Udina M, Castellvi P, Moreno-Espana J, Navines R, Valdes M, Forns X, et al. Interferon-induced depression in chronic hepatitis C: a systematic review and meta-analysis. J Clin Psychiatry. 2012; 73(8): 1128-38[DOI][PubMed]
  • 52. McNutt MD, Liu S, Manatunga A, Royster EB, Raison CL, Woolwine BJ, et al. Neurobehavioral effects of interferon-alpha in patients with hepatitis-C: symptom dimensions and responsiveness to paroxetine. Neuropsychopharmacology. 2012; 37(6): 1444-54[DOI][PubMed]
  • 53. Baraldi S, Hepgul N, Mondelli V, Pariante CM. Symptomatic treatment of interferon-alpha-induced depression in hepatitis C: a systematic review. J Clin Psychopharmacol. 2012; 32(4): 531-43[DOI][PubMed]
  • 54. Kelly EM, Corace K, Emery J, Cooper CL. Bipolar patients can safely and successfully receive interferon-based hepatitis C antiviral treatment. Eur J Gastroenterol Hepatol. 2012; 24(7): 811-6[DOI][PubMed]
  • 55. Sheridan DA, Price DA, Schmid ML, Toms GL, Donaldson P, Neely D, et al. Apolipoprotein B-associated cholesterol is a determinant of treatment outcome in patients with chronic hepatitis C virus infection receiving anti-viral agents interferon-alpha and ribavirin. Aliment Pharmacol Ther. 2009; 29(12): 1282-90[DOI][PubMed]
  • 56. Navines R, Castellvi P, Moreno-Espana J, Gimenez D, Udina M, Canizares S, et al. Depressive and anxiety disorders in chronic hepatitis C patients: reliability and validity of the Patient Health Questionnaire. J Affect Disord. 2012; 138(3): 343-51[DOI][PubMed]
  • 57. Sockalingam S, Abbey SE, Alosaimi F, Novak M. A review of sleep disturbance in hepatitis C. J Clin Gastroenterol. 2010; 44(1): 38-45[DOI][PubMed]
  • 58. Sockalingam S, Shammi C, Stergiopoulos V. Managing the neuropsychiatric complications of hepatitis C treatment. Br J Hosp Med (Lond). 2007; 68(10): 520-5[PubMed]
  • 59. Fletcher NF, McKeating JA. Hepatitis C virus and the brain. J Viral Hepat. 2012; 19(5): 301-6[DOI][PubMed]
  • 60. Hilsabeck RC, Hassanein TI, Carlson MD, Ziegler EA, Perry W. Cognitive functioning and psychiatric symptomatology in patients with chronic hepatitis C. J Int Neuropsychol Soc. 2003; 9(6): 847-54[DOI][PubMed]
  • 61. Weissenborn K, Krause J, Bokemeyer M, Hecker H, Schuler A, Ennen JC, et al. Hepatitis C virus infection affects the brain-evidence from psychometric studies and magnetic resonance spectroscopy. J Hepatol. 2004; 41(5): 845-51[DOI][PubMed]
  • 62. Huckans M, Seelye A, Woodhouse J, Parcel T, Mull L, Schwartz D, et al. Discounting of delayed rewards and executive dysfunction in individuals infected with hepatitis C. J Clin Exp Neuropsychol. 2011; 33(2): 176-86[DOI][PubMed]
  • 63. Kramer L, Bauer E, Funk G, Hofer H, Jessner W, Steindl-Munda P, et al. Subclinical impairment of brain function in chronic hepatitis C infection. J Hepatol. 2002; 37(3): 349-54[PubMed]
  • 64. Perry W, Hilsabeck RC, Hassanein TI. Cognitive dysfunction in chronic hepatitis C: a review. Dig Dis Sci. 2008; 53(2): 307-21[DOI][PubMed]
  • 65. Quarantini LC, Miranda-Scippa A, Batista-Neves S, Powell VB, Abreu N, Abreu KC, et al. A neuropsychological study comparing patients infected with HCV and HBV without psychiatric comorbidities. J Med Virol. 2009; 81(7): 1184-8[DOI][PubMed]
  • 66. Lowry D, Coughlan B, McCarthy O, Crowe J. Investigating health-related quality of life, mood and neuropsychological test performance in a homogeneous cohort of Irish female hepatitis C patients. J Viral Hepat. 2010; 17(5): 352-9[DOI][PubMed]
  • 67. Rodrigue JR, Balistreri W, Haber B, Jonas MM, Mohan P, Molleston JP, et al. Impact of hepatitis C virus infection on children and their caregivers: quality of life, cognitive, and emotional outcomes. J Pediatr Gastroenterol Nutr. 2009; 48(3): 341-7[DOI][PubMed]
  • 68. Fontana RJ, Bieliauskas LA, Back-Madruga C, Lindsay KL, Litman HJ, Lok AS, et al. Cognitive function does not worsen during long-term low-dose peginterferon therapy in patients with chronic hepatitis C. Am J Gastroenterol. 2010; 105(7): 1551-60[DOI][PubMed]
  • 69. Byrnes V, Miller A, Lowry D, Hill E, Weinstein C, Alsop D, et al. Effects of anti-viral therapy and HCV clearance on cerebral metabolism and cognition. J Hepatol. 2012; 56(3): 549-56[DOI][PubMed]
  • 70. Monaco S, Ferrari S, Gajofatto A, Zanusso G, Mariotto S. HCV-Related Nervous System Disorders. Clin Dev Immunol. 2012; 2012: 236148[DOI][PubMed]
  • 71. Pattullo V, McAndrews MP, Damyanovich A, Heathcote EJ. Influence of hepatitis C virus on neurocognitive function in patients free from other risk factors: validation from therapeutic outcomes. Liver Int. 2011; 31(7): 1028-38[DOI][PubMed]
  • 72. Weissenborn K, Ennen JC, Bokemeyer M, Ahl B, Wurster U, Tillmann H, et al. Monoaminergic neurotransmission is altered in hepatitis C virus infected patients with chronic fatigue and cognitive impairment. Gut. 2006; 55(11): 1624-30[DOI][PubMed]
  • 73. Martin-Thormeyer EM, Paul RH. Drug abuse and hepatitis C infection as comorbid features of HIV associated neurocognitive disorder: neurocognitive and neuroimaging features. Neuropsychol Rev. 2009; 19(2): 215-31[DOI][PubMed]
  • 74. Crystal H, Kleyman I, Anastos K, Lazar J, Cohen M, Liu C, et al. Effects of hepatitis C and HIV on cognition in women: data from the Women's Interagency HIV Study. J Acquir Immune Defic Syndr. 2012; 59(2): 149-54[DOI][PubMed]
  • 75. Blacklaws H, Gardner A, Usher K. Irritability: an underappreciated side effect of interferon treatment for chronic hepatitis C? J Clin Nurs. 2011; 20(9-10): 1215-24[DOI][PubMed]
  • 76. Lotrich FE, Ferrell RE, Rabinovitz M, Pollock BG. Labile anger during interferon alfa treatment is associated with a polymorphism in tumor necrosis factor alpha. Clin Neuropharmacol. 2010; 33(4): 191-7[DOI][PubMed]
  • 77. Bezemer G, Van Gool AR, Fekkes D, Vrolijk JM, Hansen BE, Janssen HL, et al. Psychiatric side effects and fluctuations in serotonergic parameters in the treatment of chronic hepatitis C infection. Neuropsychobiology. 2012; 65(3): 126-32[DOI][PubMed]
  • 78. Butt G. Stigma in the context of hepatitis C: concept analysis. J Adv Nurs. 2008; 62(6): 712-24[DOI][PubMed]
  • 79. Butt G, Paterson BL, McGuinness LK. Living with the stigma of hepatitis C. West J Nurs Res. 2008; 30(2): 204-21[DOI][PubMed]
  • 80. Zickmund S, Ho EY, Masuda M, Ippolito L, LaBrecque DR. "They treated me like a leper". Stigmatization and the quality of life of patients with hepatitis C. J Gen Intern Med. 2003; 18(10): 835-44[PubMed]
  • 81. Golden J, Conroy RM, O'Dwyer AM, Golden D, Hardouin JB. Illness-related stigma, mood and adjustment to illness in persons with hepatitis C. Soc Sci Med. 2006; 63(12): 3188-98[DOI][PubMed]
  • 82. Grundy G, Beeching N. Understanding social stigma in women with hepatitis C. Nurs Stand. 2004; 19(4): 35-9[PubMed]
  • 83. Schafer A, Scheurlen M, Felten M, Kraus MR. Physician-patient relationship and disclosure behaviour in chronic hepatitis C in a group of German outpatients. Eur J Gastroenterol Hepatol. 2005; 17(12): 1387-94[PubMed]
  • 84. Moore GA, Hawley DA, Bradley P. Hepatitis C: studying stigma. Gastroenterol Nurs. 2008; 31(5): 346-52[DOI][PubMed]
  • 85. Moore GA, Hawley DA, Bradley P. Hepatitis C: experiencing stigma. Gastroenterol Nurs. 2009; 32(2): 94-104[DOI][PubMed]
  • 86. Kraus MR, Schafer A, Csef H, Scheurlen M, Faller H. Emotional state, coping styles, and somatic variables in patients with chronic hepatitis C. Psychosomatics. 2000; 41(5): 377-84[PubMed]
  • 87. Grassi L, Satriano J, Serra A, Biancosino B, Zotos S, Sighinolfi L, et al. Emotional stress, psychosocial variables and coping associated with hepatitis C virus and human immunodeficiency virus infections in intravenous drug users. Psychother Psychosom. 2002; 71(6): 342-9[PubMed]
  • 88. Sanyal C, Ingram EL, Sketris IS, Peltekian KM, Kirkland S. Coping strategies used by patients infected with hepatitis C virus who are facing medication costs. Can J Hosp Pharm. 2011; 64(2): 131-40[PubMed]
  • 89. Treloar C, Hopwood M. "Look, I'm fit, I'm positive and I'll be all right, thank you very much": coping with hepatitis C treatment and unrealistic optimism. Psychol Health Med. 2008; 13(3): 360-6[DOI][PubMed]
  • 90. Blasiole JA, Shinkunas L, Labrecque DR, Arnold RM, Zickmund SL. Mental and physical symptoms associated with lower social support for patients with hepatitis C. World J Gastroenterol. 2006; 12(29): 4665-72[PubMed]
  • 91. Evon DM, Esserman DA, Ramcharran D, Bonner JE, Fried MW. Social support and clinical outcomes during antiviral therapy for chronic hepatitis C. J Psychosom Res. 2011; 71(5): 349-56[DOI][PubMed]
  • 92. Evon DM, Ramcharran D, Belle SH, Terrault NA, Fontana RJ, Fried MW. Prospective analysis of depression during peginterferon and ribavirin therapy of chronic hepatitis C: results of the Virahep-C study. Am J Gastroenterol. 2009; 104(12): 2949-58[DOI][PubMed]
  • 93. Rowan PJ, Al-Jurdi R, Tavakoli-Tabasi S, Kunik ME, Satrom SL, El-Serag HB. Physical and psychosocial contributors to quality of life in veterans with hepatitis C not on antiviral therapy. J Clin Gastroenterol. 2005; 39(8): 731-6[PubMed]
  • 94. Cormier M. The role of hepatitis C support groups. Gastroenterol Nurs. 2005; 28(3 Suppl)-9[PubMed]
  • 95. Edlin BR, Kresina TF, Raymond DB, Carden MR, Gourevitch MN, Rich JD, et al. Overcoming barriers to prevention, care, and treatment of hepatitis C in illicit drug users. Clin Infect Dis. 2005; 40 Suppl 5-85[DOI][PubMed]
  • 96. Loftis JM, Matthews AM, Hauser P. Psychiatric and substance use disorders in individuals with hepatitis C: epidemiology and management. Drugs. 2006; 66(2): 155-74[PubMed]
  • 97. Khokhar OS, Lewis JH. Reasons why patients infected with chronic hepatitis C virus choose to defer treatment: do they alter their decision with time? Dig Dis Sci. 2007; 52(5): 1168-76[DOI][PubMed]
  • 98. Hatem C, Minello A, Bresson-Hadni S, Jooste V, Evrard P, Obert B, et al. Is the management of hepatitis C patients appropriate? A population-based study. Aliment Pharmacol Ther. 2005; 21(8): 1007-15[DOI][PubMed]
  • 99. Jecker NS. Caring for "socially undesirable" patients. Camb Q Healthc Ethics. 1996; 5(4): 500-10[PubMed]
  • 100. Lang JP, Michel L, Melin P, Schoeffler M, Gauchet A, Rousseaux C, et al. Management of psychiatric disorders and addictive behaviors in patients with viral hepatitis C in France. Gastroenterol Clin Biol. 2009; 33(1 Pt 1): 1-7[DOI][PubMed]
  • 101. Knott A, Dieperink E, Willenbring ML, Heit S, Durfee JM, Wingert M, et al. Integrated psychiatric/medical care in a chronic hepatitis C clinic: effect on antiviral treatment evaluation and outcomes. Am J Gastroenterol. 2006; 101(10): 2254-62[DOI][PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:

Author(s):

Article(s):

Create Citiation Alert
via Google Reader